Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
483 results about "Andrology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Andrology (from Ancient Greek: ἀνήρ, anēr, genitive ἀνδρός, andros, "man"; and -λογία, -logia) is the medical specialty that deals with male health, particularly relating to the problems of the male reproductive system and urological problems that are unique to men. It is the counterpart to gynaecology, which deals with medical issues which are specific to female health, especially reproductive and urologic health.
Medicament for treating prostate diseases
InactiveUS7582294B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsNatural antibodyHeifer calf
A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors.
Owner:EPSHTEIN OLEG I
Media and method for treating pathological syndrome
InactiveUS7572441B2Energy modified materialsImmunoglobulins against cytokines/lymphokines/interferonsNatural antibodyUltra low dose
A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors.
Owner:EPSHTEIN OLEG I
Activin-actriia antagonists and uses for decreasing or inhibiting FSH secretion
ActiveUS20090118188A1Inhibit growthAvoid survivalHormone peptidesPeptide/protein ingredientsAndrologyPlant Germ Cells
In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
Owner:ACCELERON PHARMA INC
Enhancement of endogenous gonadotropin production
Provided herein is a method of enhancing endogenous gonadotropin and androgen production comprising administering a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment.
Owner:TAP PHARM PROD INC
Pharmaceutical composition based on estrogen and progesterone
InactiveUS6165491AReduce riskEffective protectionOrganic active ingredientsFemale contraceptivesProgesteronesEstradiols
Owner:EFFIK BAT
Composition and method for prevention of sexually transmitted diseases, including aids
InactiveUS6328991B1Easy to insertEasy to removeMedical devicesPharmaceutical delivery mechanismDiseaseChemical composition
A chemical composition, method and product for administration into the vaginal canal. The composition, method and product are effective in preventing the spread of sexually transmitted diseases, including the spread of AIDS.
Owner:MYHLING JOHN
Pulmonary administration of dry powder formulations for treating infertility
Provided are stabilized follicle stimulating protein (FSP) dry powder compositions for aerosolized delivery to the deep lung, methods of preparing and administering such compositions, and methods for treating infertility involving administering the dry powders by pulmonary delivery to the deep lung.
Owner:NOVARTIS FARMA
Endometriosis treatment protocol
The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.
Owner:SHIPPEN EUGENE R
Methods of inducing ovulation using a non-polypeptide camp level modulator
InactiveUS20050148501A1Reduce the possibilityGood effectBiocidePeptide/protein ingredientsOvulation timesLuteal phase
The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.
Owner:MERCK SERONO SA
Bupropion metabolites and methods of use
Owner:SEPACOR INC
Vaginal probe
A method for tissue bioassay comprising the steps of placing in the vagina of a female mammal an elongated probe having at least two electrodes positioned close to an insertion end of the probe, none of the electrodes extending around the entire periphery of said probe and at least one of then being metallic, applying across the electrodes an alternating voltage of relatively low peak-to-peak amplitude, measuring across the electrodes a value representative of the phase of the reproductive cycle of the female or the hormonal status of the fornix epitheliurn, and comparing that value with at least one reference value. A probe for practicing this method also is disclosed.
Owner:KIRSNER VACLAV
Use of GnRH agonists to support the luteal phase during infertility treatment
The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.
Owner:PREGLEM
Treatment of sexual dysfunction
Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1 / BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.
Owner:WARNER-LAMBERT CO
Medicinal agent for treating erectile dysfunction
A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile dysfunctions and vegetative disturbances of male climax by regulating the level of cyclic guanosine monophosphate (cGMP) in the cavernous bodies on sexual stimulation, the method being characterized by the use of activated forms of ultra-low doses of antibodies to the entire molecule of the endothelial NO synthase or to its polypeptide fragments, activated forms being prepared by multiple consecutive dilutions and exposure to external factors.
Owner:EPSHTEIN OLEG I
Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
InactiveUS7704983B1Avoid bleedingAvoid problemsOrganic active ingredientsBiocideSide effectBreak-through bleeding
Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and / or withdrawal amenorrhea, by periodically inducing menses with an antiprogestin.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL
Treatment of infertility
InactiveUS6585982B1Easy to optimizeIVF can be improved substantiallyOrganic active ingredientsPeptide/protein ingredientsMeiosisInfertility
Owner:NOVO NORDISK AS
Methods and systems for assessment of clinical infertility
ActiveUS20100036192A1Promote successionEase of evaluationBiostatisticsVeterinary instrumentsEmbryoInfertility
Methods and computer-based systems for facilitating assessment of clinical infertility are provided. The methods and systems can be implemented to, for example, facilitate assessment of a subject for an in vitro fertilization treatment cycle, including determining probability of a live birth event. The methods and systems can be implemented to, for example, facilitate a determination of success implantation of embryos, selection of an optimal number of embryos to transfer, and determination of success in subsequent in vitro fertilization treatment cycles following an unsuccessful treatment cycle.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
InactiveUS20110104289A1Decrease administration frequencyReduce the amount requiredOrganic active ingredientsPowder deliveryProgesterone levelProgesterones
Owner:POSI VISIONARY SOLUTIONS
Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
ActiveUS7960343B2Distribution moreMany formatsHormone peptidesPeptide/protein ingredientsGerm cellAntagonist
In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
Owner:ACCELERON PHARMA INC
Treatment of male sexual dysfunction
InactiveUS20030119714A1Reducing and eliminating prospectDrop in blood pressureBiocideDisease diagnosisNPY-Y1 receptorMale genitalia
The use of an inhibitor of a neuropeptide Y (NPY), preferably of a NPY Y1 receptor, which inhibitor is selective for an NPY or NPY Y1 receptor associated with male genitalia, in the preparation / manufacture of a medicament for the treatment or prevention of male erectile dysfunction (MED).
Owner:PFIZER INC
Progesterone injection and method for preparing the same
InactiveCN101152186AEasy to prepareSmall and uniform particle sizeOrganic active ingredientsEmulsion deliveryAntioxidantProgesterones
The invention provides a progesterone injection and the preparation method, which solves the problems of strong pungency, inconvenient use with prior progesterone injection, the problems of low stability and poor quality with prior progesterone micoremulsion, and the problems of high cost with asepsis preparation process. The weight percentage of the progesterone injection is: 0.5 to 2 percent of progesterone, 15 to 35 percent of oil for injection, 1 to 12 percent of emulsifier, 0.1 to 1 percent of assistant emulsifier, 0.2 to 2 percent of stabilizer, 0.01 to 2.5 percent of zntioxidant and allowance of water.
Owner:曲靖平和安康医药保健有限公司
Enhancement of Endogenous Gonadotropin Production
InactiveUS20070232548A1Enhancing and increasing productionImprove the level ofHormone peptidesPeptide/protein ingredientsAndrogenAgonist
Provided herein is a method of enhancing endogenous gonadotropin and androgen production comprising administering a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment.
Owner:TANEJA RAJNEESH
Use of KPV tripeptide for dermatological disorders
InactiveUS6894028B2Preventing dermatological disorders and their associated symptomatolgyCosmetic preparationsHair removalDiseaseDermatological disorders
The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment and prevention of dermatological disorders. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above.
Owner:MSH BIOPHARMA
Respiratory tract delivery of interferon-tau
InactiveUS20070243163A1Improve solubilityImprove stabilityPowder deliverySpray deliveryDiseaseWhole body
Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.
Owner:PEPGEN CORP
Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
Owner:CACAO BIO TECH
Male external catheters
InactiveUS6805690B2Reduce and eliminate irritation and discomfortSkin healthNon-surgical orthopedic devicesBodily discharge devicesMale genderExternal catheter
The invention provides male external catheters having kink-resistant drainage stems as well as methods for making male external catheters having kink-resistant drainage stems. Specifically, the invention provides male external catheters having a drainage stem designed to reduce or prevent kinking that can occur during use when a drainage hose fitting and drainage hose are attached to the catheter. The invention also provides male external catheters having skin-friendly compounds and methods for making male external catheters having skin-friendly compounds. Specifically, the invention provides male external catheters designed to have skin-friendly compounds that contact the user's skin when the catheter is being used.
Owner:COLOPLAST AS
Method for determining hCG levels in fluid samples
ActiveUS7989217B2Bioreactor/fermenter combinationsBiological substance pretreatmentsPolyclonal antibodiesPhases of clinical research
The subject invention is an immunoassay for the semi-quantitative test kit for determination of human chrionic gonadtropin (hCG) in fluid sample (such as urine) as an aid in the diagnosis of a certain stage of pregnancy. The test device includes five strips having each having a dipping end or sample ends where sample can be applied. Results are indicated by coloration of two bands across a clear area of the strips, one band being coated with a reagent such as hCG antigens and the other with a reagent such as goat / rabbit polyclonal antibody gold conjugate. The combination of color indications on the bands provides the test results.
Owner:AMERITEK USA
Method of treating for impotence and apparatus particularly useful in such method
InactiveUS20010007080A1Improve abilitiesRigid enoughSurgical instrument detailsNon-surgical orthopedic devicesPenile erectionsWavelength
Owner:INVENTIS
Increasing pregnancy rates
InactiveUS20090036384A1Increase the number ofIncrease probabilityOrganic active ingredientsPeptide/protein ingredientsProgesteronesPregnancy rate
The invention relates to a stable formulation for controlling oestrus in a subject. The formulation comprises Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof, progesterone or an analogue thereof, and an acceptable carrier.
Owner:PARNELL TECH
Method of treating female sexual dysfunction with a PDE1 inhibitor
The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and / or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.
Owner:INTRA CELLULAR THERAPIES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com